Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues.

Abstract

BACKGROUND:

Trastuzumab has significantly improved the prognosis of breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2). This result has been achieved in all disease settings, by increasing overall survival in early stage and advanced disease and by increasing pathological complete responses in neoadjuvant disease.

OBJECTIVE:

Although the greatest impact of this monoclonal antibody has been seen in the adjuvant setting, by increasing disease-free survival and overall survival rates an increased rate of both symptomatic and non-symptomatic cardiac toxicity has also been observed.

METHODS:

In the following review, the different mechanisms of trastuzumab cardiac toxicity are described and, in addition, the clinical data coming from both trials and meta-analyses is discussed.

RESULTS:

While there is strong evidence for the incidence of trastuzumab-related cardiac toxicity, there is still little known on the exact pathogenesis of this toxicity. Interestingly, both experimental and clinical data suggest that trastuzumab may sensitize cardiomyocytes to injuries and stress from administration of anthracyclines. This has led to a proposed novel mechanism of cardiotoxicity that appears to be quite different from the anthracycline-associated cardiotoxicity. Trastuzumab does not seem to cause any overt ultrastructural abnormality; it does, however, lead to myocardial dysfunction.

CONCLUSION:

Most of the proposed hypotheses seems to be related to the activity of trastuzumab in interfering with the ERBB-2 receptor. Indeed, data from clinical trials in the adjuvant setting report increased cardiac toxicity in those patients who previously received anthracyclines.

• Authors: Emilio Bria, Federica Cuppone, Michele Milella, Sunil Verma, Paolo Carlini, Cecilia Nisticò, Vanja Vaccaro, Antonio Rossi, Giuseppe Tonini, Francesco Cognetti, Edmondo Terzoli
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 8 Issue 12 Pg. 1963-71 (Dec 2008) ISSN: 1744-7682 [Electronic] England
• PMID: 18990083 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Trastuzumab

Topics

• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Clinical Trials as Topic
• Heart (drug effects)
• Humans
• Prognosis
• Survival Rate
• Trastuzumab